finafloxacin otic (Rx)

Brand and Other Names:Xtoro
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

otic suspension

  • 0.3% (5 mL/bottle)

Otitis Externa

Indicated for treatment of acute otitis externa caused by Pseudomonas aeruginosa and Staphylococcus aureus

Instill 4 gtt in affected ear(s) BID x7 days

For patients requiring use of an otowick, the initial dose can be doubled (to 8 drops), followed by 4 drops instilled into the affected ear BID x7 days

Dosage Forms & Strengths

otic suspension

  • 0.3% (5 mL/bottle)

Otitis Externa

Indicated for treatment of acute otitis externa caused by Pseudomonas aeruginosa and Staphylococcus aureus

<1 year: Safety and efficacy not established

≥1 year: Instill 4 gtt in affected ear(s) BID x7 days

For patients requiring use of an otowick, the initial dose can be doubled (to 8 drops), followed by 4 drops instilled into the affected ear BID x7 days

Next:

Adverse Effects

1-10%

Pruritus (1%)

Nausea (1%)

Previous
Next:

Warnings

Contraindications

None

Cautions

As with other antibacterial preparations, prolonged use may result in overgrowth of resistant organisms including yeast and fungi

Allergic reactions may occur in patients with a history of hypersensitivity to finafloxacin, to other quinolones, or to any of the components in this medication; if allergic reaction occurs, discontinue use and institute alternative therapy

Previous
Next:

Pregnancy & Lactation

Pregnancy

Pregnancy Category: C

Shown to be teratogenic in rabbits and rats following oral administration; neural tube defects and skeletal anomalies in both species, and limb anomalies in rabbits, were observed at exposures estimated to be at least 1300 times the maximum human systemic exposure following topical otic administration of 0.3% finafloxacin

Because animal studies are not always predictive of human responses, use during pregnancy only if the potential benefit justifies the potential risk to the fetus

Lactation

Identified in the milk of nursing rats following oral administration

The human systemic concentration following topical otic treatment is low; it is not known whether topical otic administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk

Caution should be exercised when finafloxacin is administered to a nursing mother

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Quinolone antimicrobial; inhibits bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair and recombination

Pharmacokinetics

Quantifiable systemic concentrations

  • 4 gtt BID each ear x 7 days: 0.05 ng/mL (2 of 14 healthy volunteers)
  • 4 or 8 gtt each ear single dose: up to 0.234 ng/mL (2 of 36 AOE patients)
Previous
Next:

Administration

Instructions

Warm the suspension by holding the bottle in the hand for 1-2 minutes prior to dosing in order to avoid dizziness which may result from the instillation of a cold suspension

Shake bottle well before use

Lie with the affected ear upward, instill the drops, and maintain the position for 60 seconds to facilitate penetration of the drops into the ear canal

Repeat if necessary for the opposite ear

Storage

  • Store at 2-25°C (36-77°F)
  • Do not freeze
Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.